
GW Pharma appoints president and moves CEO to US
pharmafile | May 22, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GW Pharmaceuticals, Julian Gangolli
US biopharma firm GW Pharmaceuticals has appointed Julian Gangolli as president of its North American division, and is also relocating its chief executive Justin Gover to the US.
Gangolli (pictured) was the president of the North American pharma division of Allergan from 2004 until April this year, and was a corporate VP and member of its executive committee there.
Gangolli joins GW in June and is also expected to be appointed to the company’s board of directors.
Gangolli says: “I wish to bring my experience of building a successful business for Allergan to GW and look forward to working with Justin and the entire GW team to optimise the company’s prospects in this key market.”
GW will locate its US operation in Southern California where Gangolli and Gover will be based.
Dr Geoffrey Guy who is GW’s chairman, adds: “Julian’s deep experience at building and running a major US pharmaceutical business built on speciality products will be complemented by the relocation of Justin to the US with his intimate knowledge of GW, its products and pipeline.
“Together, they will spearhead GW’s growth in the US and help to bring much needed new treatments to patients.”
Related Content

Cannabidiol drug found to aid in devastating childhood epilepsy condition
A treatment derived from cannabis has been found to produce remarkable results in children who …

GW Pharma releases positive data on cannabidiol-based Phase III trial
GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called …

Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…
Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing …






